2005
Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia
Woods SW, Gueorguieva RV, Baker CB, Makuch RW. Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia. JAMA Psychiatry 2005, 62: 961-970. PMID: 16143728, DOI: 10.1001/archpsyc.62.9.961.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsBrief Psychiatric Rating ScaleDouble-Blind MethodDrug Administration ScheduleFemaleHumansMalePlacebosPsychotic DisordersRandomized Controlled Trials as TopicResearch DesignSchizophreniaSchizophrenic PsychologySelection BiasSeverity of Illness IndexSex FactorsTreatment OutcomeConceptsBrief Psychiatric Rating ScalePlacebo-controlled trialPsychiatric Rating ScalePlacebo-controlled studyAtypical antipsychotic medicationsDose-controlled studyMedication trialsAntipsychotic medicationRating ScaleDouble-blind clinical trialNew atypical antipsychotic medicationsDose-controlled trialsTreatment completion ratesPlacebo control groupEnd point changePercentage of menDrug Administration databaseRandom effects analysisIll adultsMedication armClinical trialsNew medicationsNovel medicationsSame drugAverage age
1988
Statistical Methods for the Analysis of HIV-1 Core Polypeptide Antigen Data in Clinical Studies
Makuch R, Parks W. Statistical Methods for the Analysis of HIV-1 Core Polypeptide Antigen Data in Clinical Studies. AIDS Research And Human Retroviruses 1988, 4: 305-316. PMID: 3061416, DOI: 10.1089/aid.1988.4.305.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsInitiation of therapyPlacebo-controlled studyHIV-1 antigensDemonstrated clinical efficacyHIV-1 coreAntiretroviral effectClinical efficacyAIDS patientsAntiretroviral activityClinical studiesLymphocyte culturesVirus expressionSerum dataAntigen dataPatientsSurvival analysis methodsLaboratory dataAZTGroup differencesMost laboratory dataCulture dataStatistical methodsSignificant declineSerum